Critical considerations of matrix selection in LC–MS bioanalysis for toxicokinetic and pharmacokinetic assessment in drug development

BioanalysisVol. 13, No. 8 EditorialCritical considerations of matrix selection in LC–MS bioanalysis for toxicokinetic and pharmacokinetic assessment in drug developmentYunlin Fu, Wenkui Li & Jimmy FlarakosYunlin Fu*Author for correspondence: Tel.: +1 862 778 1726; E-mail Address: yunlin.fu@novartis.comPharmacokinetic Sciences, Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USA, Wenkui Li https://orcid.org/0000-0002-1021-2766Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USA & Jimmy FlarakosPharmacokinetic Sciences, Novartis Institutes for BioMedical Research, East Hanover, NJ 07936, USAPublished Online:17 Mar 2021https://doi.org/10.4155/bio-2020-0319AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: bioanalysisblood/plasma distributionblood stabilitymatrix selectionplasmaprotein bindingstabilitywhole bloodReferences1. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11), 1791–1796 (2010).Link, CAS, Google Scholar2. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 12(3), 290–293 (2010).Crossref, Medline, CAS, Google Scholar3. Spruill WJ, Wade WE, Dipiro JT, Blouin RA, Pruemer JM. Lesson 2 basic pharmacokinetics. Concepts in Clinical Pharmacokinetics Lesson (6th Edition) ASHP, 21–30 (2014).Google Scholar4. Lensmeyer GL, Wiebe DA, Carlson IH. Distribution of cyclosporin A metabolites among plasma and cells in whole blood: effect of temperature, hematocrit, and metabolite concentration. Clin. Chem. 35(1), 56–63 (1989).Crossref, Medline, CAS, Google Scholar5. Gidal BE, Lensmeyer GL. Therapeutic monitoring of topiramate: evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method. Ther. Drug Monit. 21(5), 567 (1999).Crossref, Medline, CAS, Google Scholar6. Li W, Williams SM, Smith HT, Tse FLS. Quantitative analysis of NIM811, a cyclophilin inhibitor, in human dried blood spots using liquid chromatography–tandem mass spectrometry. J. Chromatogr. B Analyt Technol Biomed Life Sci. 879(24), 2376–2382 (2011).Crossref, Medline, CAS, Google Scholar7. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49–65 (2010).Crossref, Medline, Google Scholar8. Kok MGM, Fillet M. Volumetric absorptive microsampling: current advances and applications. J. Pharm. Biomed. Anal. 147, 288–296 (2018).Crossref, Medline, CAS, Google Scholar9. Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin. Pharmacokinet. 2(4), 252–268 (1977).Crossref, Medline, CAS, Google Scholar10. Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin. Microbiol. Rev. 26(2), 274–288 (2013).Crossref, Medline, CAS, Google Scholar11. Sheu M-T, Wu C-Y, Su C-Y, Ho H-O. Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC–MS/MS: application to pharmacokinetic studies. Sci. Rep. 7(1), 14609 (2017).Crossref, Medline, Google Scholar12. Nation RL, Theuretzbacher U, Tsuji BT. Concentration-dependent plasma protein binding: expect the unexpected. Eur. J. Pharm. Sci. 122, 341–346 (2018).Crossref, Medline, CAS, Google Scholar13. Love I, Smith GT, Hill HM. Assessment of whole blood stability and blood/plasma distribution of drugs. In: Handbook of LC–MS Bioanalysis. Li WZhang JTse FL, (Eds). John Wiley & Sons, NJ, USA, 129–138 (2013).Crossref, Google Scholar14. Fleuren HLJ, Van Rossum JM. Nonlinear relationship between plasma and red blood cell pharmacokinetics of chlorthalidone in man. J. Pharmacokinet. Biopharm. 5(4), 359–375 (1977).Crossref, Medline, CAS, Google Scholar15. Li W, Zhang J, Tse FL. Strategies in quantitative LC–MS/MS analysis of unstable small molecules in biological matrices. Biomed. Chromatogr. 25(1-2), 258–277 (2011).Crossref, Medline, Google Scholar16. Ledvina AR, Ewles M, Pang Y, Cape S. Whole blood stability in quantitative bioanalysis. Bioanalysis 11(20), 1885–1897 (2019).Link, CAS, Google Scholar17. Jain DS, Subbaiah G, Sanyal M, Pande UC, Shrivastav P. Liquid chromatography–tandem mass spectrometry validated method for the estimation of indapamide in human whole blood. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 834(1-2), 149–154 (2006).Crossref, Medline, CAS, Google Scholar18. Brockman AH, Hatsis P, Paton M, Wu J-T. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal. Chem. 79(4), 1599–1603 (2007).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByToxicokinetics in preclinical drug development of small‐molecule new chemical entities13 December 2022 | Biomedical Chromatography, Vol. 50 Vol. 13, No. 8 Follow us on social media for the latest updates Metrics Downloaded 226 times History Received 7 December 2020 Accepted 18 February 2021 Published online 17 March 2021 Published in print April 2021 Information© 2021 Newlands PressKeywordsbioanalysisblood/plasma distributionblood stabilitymatrix selectionplasmaprotein bindingstabilitywhole bloodFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download